Avadel Pharmaceuticals (AVDL) Retained Earnings: 2009-2022
Historic Retained Earnings for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to -$557.8 million.
- Avadel Pharmaceuticals' Retained Earnings fell 31.10% to -$557.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$557.8 million, marking a year-over-year decrease of 31.10%. This contributed to the annual value of -$447.8 million for FY2021, which is 16.55% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Retained Earnings of -$557.8 million as of Q3 2022, which was down 3.75% from -$537.6 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Retained Earnings registered a high of -$274.9 million during Q1 2018, and its lowest value of -$557.8 million during Q3 2022.
- For the 3-year period, Avadel Pharmaceuticals' Retained Earnings averaged around -$431.0 million, with its median value being -$403.5 million (2021).
- Its Retained Earnings has fluctuated over the past 5 years, first rose by 9.88% in 2018, then slumped by 36.37% in 2019.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Retained Earnings stood at -$358.0 million in 2018, then dropped by 9.28% to -$391.2 million in 2019, then grew by 1.80% to -$384.2 million in 2020, then declined by 16.55% to -$447.8 million in 2021, then slumped by 31.10% to -$557.8 million in 2022.
- Its Retained Earnings stands at -$557.8 million for Q3 2022, versus -$537.6 million for Q2 2022 and -$474.2 million for Q1 2022.